Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies.

Abstract excerpt

The most common driver gene mutation in patients with non-small-cell lung cancer (NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of EGFR-tyrosine kinase inhibitors, the treatment prospects and prognosis of NSCLC patients with EGFR-sensitive mutations have significantly improved. Nonetheless, therapies targeting NSCLC are still associated with a risk of primary or secondary...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adaptation, Psychological
• Share to Carcinoma, Non-Small-Cell Lung
• Share to Drug Resistance, Neoplasm